204 related articles for article (PubMed ID: 35190207)
1. Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario.
Lee GY; Inthasorn P; Laowahutanont P; Lawpoolsri S; Kamolratanakul S; Lungchukiet P; Oh J; Termrungruanglert W; Taechakraichana N; Pitisuttithum P
Vaccine; 2022 Mar; 40(13):1968-1976. PubMed ID: 35190207
[TBL] [Abstract][Full Text] [Related]
2. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J-HERS 2021 multicenter study.
Saeki Y; Saito M; Irie T; Itoh F; Enatsu A; Komura H; Fujii M; Fujii R; Hidaka N; Maehama T; Shirasu N; Waseda T; Shibata T; Takada E; Mibe K; Sakamoto J; Yamada S; Takakura M; Sasagawa T
J Med Virol; 2024 Feb; 96(2):e29413. PubMed ID: 38314927
[TBL] [Abstract][Full Text] [Related]
5. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
8. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
9. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
10. Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study.
Seong J; Ryou S; Yoo M; Lee J; Kim K; Jee Y; Cho CH; Kim SM; Hong SR; Jeong DH; Lee WC; Park JS; Kim TJ; Kee MK
J Gynecol Oncol; 2020 Jan; 31(1):e4. PubMed ID: 31788994
[TBL] [Abstract][Full Text] [Related]
11. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
[TBL] [Abstract][Full Text] [Related]
12. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan.
Fujiwara H; Suzuki M; Morisawa H; Sayama M; Kimura K
Asian Pac J Cancer Prev; 2019 Jan; 20(1):81-85. PubMed ID: 30678384
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study.
Rodriguez AM; Zeybek B; Vaughn M; Westra J; Kaul S; Montealegre JR; Lin YL; Kuo YF
Cancer; 2020 Apr; 126(8):1656-1667. PubMed ID: 32037524
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
16. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
Dehlendorff C; Baandrup L; Kjaer SK
J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
[TBL] [Abstract][Full Text] [Related]
17. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
[TBL] [Abstract][Full Text] [Related]
18. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of HPV vaccination against cervical neoplasia among birth cohorts ineligible for routine vaccination.
Dong L; Nygård M; Støer NC; Klungsøyr O; Hansen BT
Int J Cancer; 2023 Jul; 153(2):399-406. PubMed ID: 36866965
[TBL] [Abstract][Full Text] [Related]
20. Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands.
Schurink-van 't Klooster TM; Siebers AG; Hoes J; van Kemenade FJ; Berkhof J; Bogaards JA; de Melker HE
Cancer Med; 2023 May; 12(10):11786-11794. PubMed ID: 36965085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
